Eli Lilly & Co. (NYSE:LLY) has reportedly finalized a $2.75 billion agreement to introduce AI-developed drugs from Hong Kong’s Insilico Medicine to the global market.
Details Of The Deal
According to a CNBC report, the deal involves an upfront payment of $115 million to Insilico, with additional payments tied to regulatory and commercial achievements, plus royalties on future sales. Insilico has created at least 28 drugs using generative AI, with nearly half already in clinical stages, according to Alex Zhavoronkov, Insilico’s CEO.
The collaboration between the two firms began with an AI-based software licensing deal in 2023. Andrew Adams, Lilly’s group vice president of Molecule Discovery, emphasized the partnership’s potential to explore new mechanisms and accelerate therapeutic candidate identification.
What Does Insilico Do?
Insilico’s AI development occurs outside China, in Canada and the Middle East, while early preclinical drug development is conducted in China. Zhavoronkov stated that AI can expedite molecule synthesis compared to traditional methods.
Zhavoronkov noted that Eli Lilly excels in certain AI areas, highlighting the company’s integration of biology, chemistry, and automation. As part of the agreement, Insilico will join Lilly’s Gateway Labs for biotech development.
Critical Timing
The partnership between Eli Lilly and Insilico Medicine comes at a crucial time for the pharmaceutical giant. Analysts have expressed concerns recently about the company’s obesity drug market projections, suggesting that expectations might be inflated. This new collaboration could diversify Lilly’s portfolio, mitigating potential risks associated with over-reliance on any single market.
Moreover, Eli Lilly has been actively working on innovative treatments, such as its experimental diabetes drug, Retatrutide, which has shown promising results in weight loss and blood sugar reduction. The integration of AI in drug development could further enhance Lilly’s ability to bring groundbreaking treatments to market more efficiently.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock
Recent Comments